Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Insider Jeffrey Dierks Sells 10,507 Shares

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Get Free Report) insider Jeffrey Dierks sold 10,507 shares of the business's stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $37.01, for a total transaction of $388,864.07. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Jeffrey Dierks also recently made the following trade(s):

• On Tuesday, October 29th, Jeffrey Dierks sold 21,496 shares of Harmony Biosciences stock. The stock was sold at an average price of $40.47, for a total value of $869,943.12.

Harmony Biosciences Price Performance

HRMY traded up $1.61 during trading on Thursday, hitting $38.54. 992,496 shares of the company traded hands, compared to its average volume of 513,855. The company has a current ratio of 3.24, a quick ratio of 3.20 and a debt-to-equity ratio of 0.28. The company has a market cap of $2.20 billion, a PE ratio of 18.27, a P/E/G ratio of 0.49 and a beta of 0.78. The stock's 50-day simple moving average is $34.26 and its two-hundred day simple moving average is $34.76. Harmony Biosciences Holdings, Inc. has a 1 year low of $28.14 and a 1 year high of $41.61.

Harmony Biosciences (NASDAQ:HRMY - Get Free Report) last issued its earnings results on Tuesday, October 29th. The company reported $0.79 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.64 by $0.15. Harmony Biosciences had a return on equity of 23.16% and a net margin of 17.98%. The firm had revenue of $186.00 million for the quarter, compared to analysts' expectations of $184.07 million. During the same period in the previous year, the firm posted $0.63 earnings per share. The business's revenue was up 16.0% compared to the same quarter last year. As a group, sell-side analysts anticipate that Harmony Biosciences Holdings, Inc. will post 2.42 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms have issued reports on HRMY. Needham & Company LLC reissued a "buy" rating and set a $52.00 price target on shares of Harmony Biosciences in a report on Monday. Mizuho increased their target price on shares of Harmony Biosciences from $42.00 to $52.00 and gave the stock an "outperform" rating in a report on Thursday, October 10th. HC Wainwright restated a "buy" rating and set a $75.00 target price on shares of Harmony Biosciences in a research note on Thursday. Raymond James reiterated an "outperform" rating and issued a $40.00 price target on shares of Harmony Biosciences in a research report on Thursday, October 10th. Finally, Oppenheimer restated an "outperform" rating and set a $59.00 price objective (up from $56.00) on shares of Harmony Biosciences in a research report on Wednesday, October 30th. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has an average rating of "Buy" and an average target price of $55.00.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Victory Capital Management Inc. raised its stake in Harmony Biosciences by 54.1% during the second quarter. Victory Capital Management Inc. now owns 84,964 shares of the company's stock valued at $2,563,000 after purchasing an additional 29,816 shares in the last quarter. American Century Companies Inc. lifted its holdings in shares of Harmony Biosciences by 53.7% in the 2nd quarter. American Century Companies Inc. now owns 681,536 shares of the company's stock valued at $20,562,000 after acquiring an additional 238,140 shares during the last quarter. Envestnet Asset Management Inc. grew its position in Harmony Biosciences by 19.8% in the second quarter. Envestnet Asset Management Inc. now owns 61,397 shares of the company's stock worth $1,852,000 after acquiring an additional 10,167 shares in the last quarter. Massachusetts Financial Services Co. MA increased its stake in Harmony Biosciences by 2.7% during the second quarter. Massachusetts Financial Services Co. MA now owns 519,701 shares of the company's stock worth $15,679,000 after acquiring an additional 13,547 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its position in Harmony Biosciences by 13.3% during the second quarter. Dimensional Fund Advisors LP now owns 956,785 shares of the company's stock valued at $28,871,000 after purchasing an additional 112,197 shares during the period. 86.23% of the stock is currently owned by institutional investors.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.